These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 35125336)

  • 1. Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma.
    Kaye DR; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Pollack CE; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB; Dinan MA
    J Geriatr Oncol; 2022 Jun; 13(5):614-623. PubMed ID: 35125336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.
    Spees LP; Wheeler SB; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Leapman M; Gross CP; Dinan MA
    Cancer Med; 2021 Oct; 10(19):6653-6665. PubMed ID: 34480518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC).
    Dinan MA; Wilson LE; Greiner MA; Spees LP; Pritchard JE; Zhang T; Kaye D; George D; Scales CD; Baggett CD; Gross CP; Leapman MS; Wheeler SB
    Urology; 2022 Oct; 168():129-136. PubMed ID: 35878815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma.
    Pritchard JE; Wilson LE; Miller SM; Greiner MA; Cohen HJ; Kaye DR; Zhang T; Dinan MA
    J Am Geriatr Soc; 2022 Aug; 70(8):2330-2343. PubMed ID: 35499667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy.
    Dzimitrowicz HE; Wilson LE; Jackson BE; Spees LP; Baggett CD; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Leapman MS; Gross CP; Dinan MA; Wheeler SB
    JCO Oncol Pract; 2023 Feb; 19(2):e213-e227. PubMed ID: 36413741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.
    Spees LP; Dinan MA; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George DJ; Scales CD; Pritchard JE; Leapman M; Gross CP; Wheeler SB
    Clin Genitourin Cancer; 2022 Oct; 20(5):e396-e405. PubMed ID: 35595633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States.
    Wilson LE; Spees L; Pritchard J; Greiner MA; Scales CD; Baggett CD; Kaye D; George DJ; Zhang T; Wheeler SB; Dinan MA
    Kidney Cancer; 2021; 5(3):115-127. PubMed ID: 34632169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.
    Wheeler SB; Spees LP; Jackson BE; Baggett CD; Wilson LE; Greiner MA; Kaye DR; Zhang T; George D; Scales CD; Pritchard JE; Dinan MA
    JCO Oncol Pract; 2021 Dec; 17(12):e1895-e1904. PubMed ID: 34138665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma.
    Chow RD; Long JB; Hassan S; Wheeler SB; Spees LP; Leapman MS; Hurwitz ME; McManus HD; Gross CP; Dinan MA
    JNCI Cancer Spectr; 2023 May; 7(3):. PubMed ID: 37202354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy.
    Forman R; Long JB; Westvold SJ; Agnish K; Mcmanus HD; Leapman MS; Hurwitz ME; Spees LP; Wheeler SB; Gross CP; Dinan MA
    JNCI Cancer Spectr; 2024 Sep; 8(5):. PubMed ID: 39133171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma.
    Rahman SN; Long JB; Westvold SJ; Leapman MS; Spees LP; Hurwitz ME; McManus HD; Gross CP; Wheeler SB; Dinan MA
    JAMA Netw Open; 2024 Apr; 7(4):e248747. PubMed ID: 38687479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma.
    Miller SM; Wilson LE; Greiner MA; Pritchard JE; Zhang T; Kaye DR; Cohen HJ; Becher RD; Maerz LL; Dinan MA
    J Geriatr Oncol; 2022 Jun; 13(5):635-643. PubMed ID: 34996724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
    Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
    Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of Care in Patients with Metastatic Renal Cell Carcinoma Among a U.S. Payer Population with Commercial or Medicare Advantage Membership.
    Miller LA; Stemkowski S; Saverno K; Lane DC; Tao Z; Hackshaw MD; Loy B
    J Manag Care Spec Pharm; 2016 Mar; 22(3):219-26. PubMed ID: 27003551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of first-line targeted therapy utilization and adherence among older adults diagnosed with metastatic renal cell carcinoma.
    Hicks BM; Chun DS; Peacock Hinton S; Hsu CD; Tan HJ; Lund JL
    J Geriatr Oncol; 2022 Apr; 13(3):325-333. PubMed ID: 34782282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma.
    Hagiwara M; Hackshaw MD; Oster G
    J Med Econ; 2013 Nov; 16(11):1300-6. PubMed ID: 24004437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of initiating oral anticancer agents for leukemia on adherence to medications for multiple chronic conditions.
    Gatwood J; Dashputre A; Rajpurohit A; Gatwood K; Mackler E; Wallace L; Farris K; Rizvi-Toner A; Farley J
    J Oncol Pharm Pract; 2024 Mar; 30(2):342-353. PubMed ID: 37113049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries.
    Doshi JA; Jahnke J; Raman S; Puckett JT; Brown VT; Ward MA; Li P; Manz CR
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1457-1468. PubMed ID: 34595957
    [No Abstract]   [Full Text] [Related]  

  • 19. Medication Adherence Among Adults With Comorbid Chronic Conditions Initiating Oral Anticancer Agent Therapy for Multiple Myeloma.
    Gatwood J; Dashputre A; Rajpurohit A; Gatwood K; Mackler E; Wallace L; Farris K; Rizvi-Toner A; Farley J
    JCO Oncol Pract; 2022 Sep; 18(9):e1475-e1483. PubMed ID: 35700416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physician visits and the timing of skeletal-related events among men newly diagnosed with metastatic prostate cancer: A cohort analysis.
    Onukwugha E; Albarmawi H; Sun K; Mullins CD; Aly A; Hussain A
    Urol Oncol; 2018 Jul; 36(7):340.e23-340.e31. PubMed ID: 29724482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.